FDA actions, week of November 16, 2026: 1 approval, 1 proposed rule
The FDA published 2 actions so far in the week of November 16 to 22, 2026: 1 approval announcement and 1 proposed rule in the Federal Register.
Compiled by code from the stream briefs and public records linked below; no model wrote this page. How we use automation
Each line below links the stream brief and the agency's own record, grouped by the type of record.
This page updates as the week's records arrive. The week ends on Sunday, November 22, 2026.
Approvals
- FDA approves giredestrant with everolimus for ESR1-mutated breast cancer. On November 16, 2026 the FDA approved giredestrant (Wilserdly) in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The approval includes the FoundationOne Liquid CDx assay as a companion diagnostic to identify ESR1 mutations. Source: FDA approval page, November 16, 2026.
Proposed rules
- FDA proposes rule that N-acetyl-L-cysteine is not excluded from the dietary supplement definition. The FDA is proposing a regulation that finds N-acetyl-L-cysteine (NAC) is not excluded from the dietary supplement definition in the FD&C Act, which would allow products containing NAC to be lawfully marketed as dietary supplements if they otherwise meet the definition. Comments on the proposed rule are due by January 19, 2027. Source: Federal Register proposed rule, November 17, 2026.
How this page is made
Code builds this page from the stream briefs linked above, grouped by the type of record. No model writes this page. Software wrote each brief from one primary record, and code checked every number and name in it against that record. The source link opens the record itself.